EUDAMED Implementation 2026: Key Changes and National Adaptations

By HEOR Staff Writer

May 22, 2026

EUDAMED Implementation 2026

The EUDAMED Implementation 2026 will require mandatory use of four key modules in the European database on medical devices from 28 May 2026. These cover registration of economic operators, device registration via UDI, notified bodies and certificates, plus market surveillance, following earlier voluntary phases and prior INFARMED communications.

Mandatory Rollout of Core EUDAMED Modules

Four modules of the European database become compulsory on 28 May 2026. The change directly supports Regulations (EU) 2017/745 and 2017/746 and builds on voluntary availability of three modules since 2024.

National System Integration and Data Reuse

Portugal’s Sistema de Informação para Dispositivos Médicos is being aligned with EUDAMED Implementation 2026 to reuse data, cut duplication and simplify national notifications. The Nomenclatura Portuguesa de Dispositivos Médicos will be gradually replaced by the European Medical Device Nomenclature while preserving existing commercial and labelling records.

Technical Preparations and Temporary Downtime

Updates to the national platform will map Código de Dispositivo Médico entries to UDI-DI data and maintain access to certificates and documentation. The system will be unavailable between 26 and 28 May 2026 to finalise these links before resuming full operation alongside the European database.

Strengthened Surveillance and Reduced Burden

The unified platform improves traceability for authorities, notified bodies and sponsors while lowering administrative workload. Public information stays openly accessible and restricted sections remain available to authorised users, preserving INFARMED’s central role in market oversight and healthcare procurement.

Reference url

Recent Posts

delpacibart braxlosiran FSHD
Delpacibart Braxlosiran FSHD Shows Promise in Disease Modification

By João L. Carapinha

June 11, 2026

Novartis has achieved a key clinical milestone with delpacibart braxlosiran FSHD, as its FORTITUDE biomarker cohort successfully met the primary endpoint by substantially suppressing DUX4-driven gene expression and reducing muscle damage markers in patients with facioscapulohumeral muscular dystr...
athlete risk stratification
Advancing Athlete Risk Stratification with Predictive Frameworks

By João L. Carapinha

June 11, 2026

Athlete risk stratification now integrates epidemiological evidence, explainable artificial intelligence, and mechanistic cardiac models to better protect young competitors. This convergence offers a path to distinguish healthy athletic remodeling from hidden substrates that can trigger fatal arr...
Innovative Therapies Access Portugal
Evaluating Innovative Therapies Access in Portugal

By João L. Carapinha

June 11, 2026

According to Paulo Gonçalves in the APIFARMA newsletter, Innovative Therapies Access in Portugal directs resources toward therapeutic innovation at levels substantially below feasible ambitions. Protracted authorization processes impose measurab...